Literature DB >> 18000214

Absolute risk models for subtypes of breast cancer.

Mitchell H Gail, William F Anderson, Montserrat Garcia-Closas, Mark E Sherman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18000214     DOI： 10.1093/jnci/djm228

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  10 in total

1.  Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer.

Authors:  Lyndsay V Rhodes; Syreeta L Tilghman; Stephen M Boue; Shuchun Wang; Hafez Khalili; Shannon E Muir; Melyssa R Bratton; Qiang Zhang; Guangdi Wang; Matthew E Burow; Bridgette M Collins-Burow
Journal:  Oncol Lett       Date:  2011-10-24       Impact factor: 2.967

2.  Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer.

Authors:  James W Antoon; William D Meacham; Melyssa R Bratton; Evelyn M Slaughter; Lyndsay V Rhodes; Hasina B Ashe; Thomas E Wiese; Matthew E Burow; Barbara S Beckman
Journal:  J Mol Endocrinol       Date:  2011-04-28       Impact factor: 5.098

3.  Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).

Authors:  Reena S Cecchini; Joseph P Costantino; Jane A Cauley; Walter M Cronin; D Lawrence Wickerham; Hanna Bandos; Joel L Weissfeld; Norman Wolmark
Journal:  Cancer Prev Res (Phila)       Date:  2012-10-11

4.  Declining second primary ovarian cancer after first primary breast cancer.

Authors:  Sara J Schonfeld; Amy Berrington de Gonzalez; Kala Visvanathan; Ruth M Pfeiffer; William F Anderson
Journal:  J Clin Oncol       Date:  2013-01-02       Impact factor: 44.544

5.  Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer.

Authors:  James W Antoon; Martin D White; Jennifer L Driver; Matthew E Burow; Barbara S Beckman
Journal:  Exp Biol Med (Maywood)       Date:  2012-08-02

Review 6.  Key steps for effective breast cancer prevention.

Authors:  Kara L Britt; Jack Cuzick; Kelly-Anne Phillips
Journal:  Nat Rev Cancer       Date:  2020-06-11       Impact factor: 60.716

7.  netDx: interpretable patient classification using integrated patient similarity networks.

Authors:  Shraddha Pai; Shirley Hui; Ruth Isserlin; Muhammad A Shah; Hussam Kaka; Gary D Bader
Journal:  Mol Syst Biol       Date:  2019-03-14       Impact factor: 11.429

8.  Physical activity and postmenopausal breast cancer risk in the NIH-AARP diet and health study.

Authors:  Tricia M Peters; Arthur Schatzkin; Gretchen L Gierach; Steven C Moore; James V Lacey; Nicholas J Wareham; Ulf Ekelund; Albert R Hollenbeck; Michael F Leitzmann
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

9.  Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort.

Authors:  James V Lacey; Aimee R Kreimer; Saundra S Buys; Pamela M Marcus; Shih-Chen Chang; Michael F Leitzmann; Robert N Hoover; Philip C Prorok; Christine D Berg; Patricia Hartge
Journal:  BMC Cancer       Date:  2009-03-17       Impact factor: 4.430

10.  TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex.

Authors:  Wen Hsin Lee; Lee Yee Choong; Naing Naing Mon; SsuYi Lu; Qingsong Lin; Brendan Pang; Benedict Yan; Vedula Sri Ram Krishna; Himanshu Singh; Tuan Zea Tan; Jean Paul Thiery; Chwee Teck Lim; Patrick Boon Ooi Tan; Martin Johansson; Christian Harteneck; Yoon Pin Lim
Journal:  Sci Rep       Date:  2016-06-13       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.